Mechanisms of dihydrotestosterone action on resveratrol-induced anti-proliferation in breast cancer cells with different ERα status
PDF | HTML | How to cite
Metrics: PDF 2065 views | HTML 1878 views | ?
Yu-Tang Chin1,*, Sheng-Huei Yang2,*, Tung-Cheng Chang3, Chun A. Changou2,4,5, Hsuan-Yu Lai1, Earl Fu6, Wei-Chun HuangFu1,2, Paul J. Davis7,8, Hung-Yun Lin1,2, Leroy F. Liu1
1Taipei Cancer Center, Taipei Medical University, Taipei, Taiwan
2PhD program for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
3Division of Colorectal Surgery Department of Surgery, Taipei Medical University-Shuang-Ho Hospital, New Taipei City, Taiwan
4Integrated Laboratory, Center of Translational Medicine, Taipei Medical University, Taipei, Taiwan
5Core Facility, Taipei Medical University, Taipei, Taiwan
6Department of Periodontology, School of Dentistry, National Defense Medical Center and Tri-Service General Hospital, Taipei, Taiwan
7Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, New York, USA
8Albany Medical College, Albany, New York, USA
*These authors have contributed equally to this work
Wei-Chun HuangFu, e-mail: [email protected]
Hung-Yun Lin, e-mail: [email protected]
Keywords: resveratrol, DHT, estrogen receptor-α, integrin αvβ3, breast cancer
Received: May 28, 2015 Accepted: September 25, 2015 Published: October 06, 2015
Dihydrotestosterone (DHT) has been shown to promote breast cancer growth via different mechanisms. In addition to binding to ERα, the DHT membrane receptor exists on integrin αvβ3. Resveratrol induces p53-dependent apoptosis via plasma membrane integrin αvβ3. Resveratrol and DHT signals are both transduced by activated ERK1/2; however, DHT promotes cell proliferation in cancer cells, whereas resveratrol is pro-apoptotic. In this study, we examined the mechanism by which DHT inhibits resveratrol-induced apoptosis in human ERα positive (MCF-7) and negative (MDA-MB-231) breast cancer cells. DHT inhibited resveratrol-stimulated phosphorylation of Ser-15 of p53 in a concentration-dependent manner. These effects of DHT on resveratrol action were blocked by an ERα antagonist, ICI 182,780, in MCF-7 breast cancer cells. DHT inhibited resveratrol-induced nuclear complex of p53-COX-2 formation which is required p53-dependent apoptosis. ChIP studies of COX-2/p53 binding to DNA and expression of p53-responsive genes indicated that DHT inhibited resveratrol-induced p53-directed transcriptional activity. In addition, DHT did inhibit resveratrol-induced COX-2/p53-dependent gene expression. These results suggest that DHT inhibits p53-dependent apoptosis in breast cancer cells by interfering with nuclear COX-2 accumulation which is essential for stimulation of apoptotic pathways. Thus, the surface receptor sites for resveratrol and DHT are discrete and activate ERK1/2-dependent downstream effects on apoptosis that are distinctive. These studies provide new insights into the antagonizing effects of resveratrol versus DHT, an important step toward better understanding and eventually treating breast cancer. It also indicates the complex pathways by which apoptosis is induced by resveratrol in DHT-depleted and -repleted environments.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.